Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982917 | 0.85 | L3MBTL1 (0.58) | XDHGAAL3MBTL1LMNAHTT | |
| SCHEMBL29437991 | 0.85 | L3MBTL1 (0.58) | XDHGAAL3MBTL1LMNAHTT | |
| SCHEMBL12594083 | 0.82 | GLA (0.42) | GAAL3MBTL1LMNAHTTVCAM1 | |
| SCHEMBL13832419 | 0.79 | CYP19A1 (0.36) | ALDH1A1ARCYP19A1 | |
| SCHEMBL31016173 | 0.77 | XDH (0.45) | XDHLMNAVCAM1ALDH1A1HSPB1 | |
| SCHEMBL3173442 | 0.74 | XDH (0.60) | XDHGAALMNAHTTVCAM1 | |
| SCHEMBL28482089 | 0.72 | ALDH1A1 (0.51) | LMNAHTTALDH1A1HSPB1NPC1 | |
| SCHEMBL22534743 | 0.72 | HSPB1 (0.48) | GAAL3MBTL1LMNAHTTALDH1A1 | |
| SCHEMBL16528427 | 0.70 | MAPT (0.48) | XDHGAAL3MBTL1LMNAHTT | |
| SCHEMBL22534742 | 0.70 | HSPB1 (0.68) | GAAL3MBTL1LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-20140206713-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-2509961-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | Autifony Therapeutics Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | XDH 3104/4885GAA 3716/4885L3MBTL1 4332/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | XDH 3302/4885GAA 3733/4885L3MBTL1 4300/4885 |
| US-20140206713-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | XDH 277/4885GAA 272/4885L3MBTL1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.